Richard Tobin: I'll take the second one first. I know, I think it's just a purchase, I would say no, but I think that's early days to see what happens in the space. Any activity in the space in total is interesting. I'll leave it at that. In terms of M&A, yes, we took some cost in Q1 around inorganic activity. So, I guess that's an indication that we're working on some things that we hope to get across the line. I can tell you, overall, there's not a lot coming to market for all the reasons we can understand. But the good news is that multiples are now converged with the public markets and the competitiveness or lack of PE participation is helpful. So more to come, but I think that we're pleased with what we got going on in the pipeline.
Richard Tobin: Yes. This was more of a one particular customer basically revisiting strategically what their intent is. So it's our customer. We expect that process to take somewhere between four to six months, and at that point, we go back. It just wasn't -- we could have kicked the can here and just left it in backlog, but then it becomes a problem in terms of inventory in our planning process. So we just took the -- we just made the decision just to debook it out of backlog, it is a one-off. I mean, right now, what I'm hearing -- what we're hearing from our clients is, again, they're still having trouble getting the labor. They're still unhappy with the inflation cost of doing their builds, but they'd continue to like to do the build. So the demand is still strong. This one is just a strategic issue as opposed to kind of an overall commentary on the market.
Richard Tobin: Yes. I mean I think that we would have expected to build some of that product in Q2. So, that's a bit of a headwind there. But quite frankly, the bigger issue for Q2 is the last remaining quarter of bio and EMV. So to me, Q2 is always going to be, from a comp point of view, sort of like Q1 to a certain extent, but we really feel good about the back half of the year because the comps roll forward and all of the bottom below the line charges, call it that, for a lack of a better word, actually roll positive. So yes, I mean, Q2 should look a lot like Q1 relative comp to comp.
Richard Tobin: No, I mean, I wouldn't get too hung up on trying to monetize the math on the door cancellation. It is a bit of a headwind in Q2. What I'm saying is, if you look at Q1 to Q1, Q2 is going to be similar in terms of Q2 to Q2 comp. There's a step up in volume there.
Richard Tobin: I think we're not really taking any more meaningful price action. I mean, I think in certain areas, yes, but I mean, I think we're happy to just continue to get what's already baked into the system.
Richard Tobin: Oh, boy. Orders in Q1 were better than we had modeled. And interestingly, just to give a little color of it, it was all in March. So it was tracking the way that we thought it was going to track. We would expect it to be below one in Q1 just because of the size of the backlog and the non need to order so far in advance, but March was very healthy. So it's early days. If that pace keeps up, that's great for our full year volume forecast, but like I said before in the comments, we don't need to be above one every quarter for the balance of the year to hit our numbers. So, it's early days. I think that overall, we're pleased with the book-to-bill of Q1 because it's a little bit better than expected. Remember, but you have to recall, remember numerator and denominator Q2 and Q3, we step up on the shipment side, right? So you need almost a greater inflection of orders to stay above one from there. So, we'll see how it goes, but will take better-than-expected book-to-bill in Q1 [indiscernible].
Richard Tobin: Well, we're very prospective on the CO2 systems and on the heat exchanger side, which is the reason that we're expanding capacity. So that capacity is going to take basically the balance of the year to progressively come online. We probably could sell some of that capacity if it was in place now, but we think that we still in the March in terms of our capacity build versus our competitors there. So, we're bringing it online as fast as we can, but you can't sacrifice quality, and there's a variety of other things that you need to do to get it done. The swing factor will be, as I mentioned in the comments, that we have some interesting projects in Belvac, which we would expected Belvac to cycle down some in Q2, which I think we talked about at the beginning of the year. If we were able to book that, that would be a positive in terms of back-end growth. And look, at the end of the day, we expect to rebook the refrigeration business in the second half of the year. But I will tell you that, that cost structure of that business is much more flexible than it's been in the past. So even if we were to miss a little bit in terms of the top line growth there, I don't think that we're going to see the margin dilution that you would have seen historically.
Richard Tobin: North American dispensers, I think was a positive surprise, and we wouldn't -- we were not expecting that to inflect until the back half of the year. Heat exchangers, I mean, I think that if we really wanted to go get the orders now, we could basically book the balance of the year in terms of backlog. That's been good. Printing ID, if you look at the performance of Q1 has been excellent. I mean that's a business that I don't think anybody models an 8% growth rate there at some really good margins. So, I mean it's broad-based in the portfolio. I think what we're most pleased with, I guess, is that biopharma inflected, right? Because we -- you see our customers now reporting their earnings of the week. We were kind of three quarters in front of everybody else in the destocking. So, we feel good about basically this inflecting in the second half of the year. And I think that we've had a more positive view, I think, on retail fueling then, I guess, the market would expect and if March orders are a precursor, I think we feel good about our full year estimates.
Richard Tobin: Well, I mean, the negative comp is less so in Q2 than Q1. It was pretty significant in Q1, as you can see from the margin performance. It's still negative in Q2 and it reflects positively in the second half. The interesting part about it is we really never lost operating margin on the lower volume. We actually preserved margins. We just lost all of the volume and all the gross margin associated with that volume. So more interesting thing about targeting 30% for the full year is the balance of that segment is growing very well, and it's dilutive to biopharma. So to get to 30%, it does -- it's interesting that if those parts of the portfolio grow significantly or at least stay on the track that they're on right now, we probably have a little bit of difficulty to reach 30% just because of the portfolio effect of the segment itself. But better news is, we've been waiting now, but biopharma looks like it turns from a headwind at the half to a tailwind going forward, and we'd expect that tailwind to be material in '24.
Richard Tobin: We have not had the time to digest what Carrier put out there in terms of the marketplace. So, I'll take a pause on that. We -- but we have been participating in the growth of the European heat pump market now for several years. I think that we are proactive in terms of building out our capacity. As we mentioned, we -- our target is to increase capacity early in '24 by 50% for SWEP. So part of winning share is to have the available capacity at the right product quality at the right price point. So that's all we can do. So we would expect that we'll be, we'll receive part of whatever estimates you want to make about what the future is in terms of heat pump growth from here, but we don't think it's just a European phenomenon. We'd expect that technology to be adopted progressively over the balance of the world driven a lot by regulation and that's why we're not just expanding our capacity in Europe, we've actually expanded in Asia and the United States also.
Richard Tobin: Yes, I can't remember the Sammy Hagar song about like one foot on the gas and one on the brake. That's the way we're trying to run it here, right. That meaning that there's a lot of macro uncertainty in the marketplace, we think that we've got some tailwinds. But we can't just be blind, of not watching our own balance sheet. And quite frankly, we've been carrying excess inventory for two years around here. So, it was natural for us to kind of liquidate. Our watch points are the businesses that we have that are subject to constriction in credit. So to pick one and not to be overtly negative here, I mean, our car wash business requires is largely driven in a certain way of entrepreneurs getting loans and building out carwash. Well, the fact of the matter is that credit is going to be tightened. Now, does that open up the door for our big retail clients to now meaningfully move into the carwash space? We'll see. So, there's a lot of moving parts here. At the end of the day, my personal view, it's going to be a consumer driven recession, and in which I think that we're going to get. I think, whether that negativity is fully offset by the amount of capital that is going into kind of the regulatory regime or reshoring or a variety of other tailwinds that we talked about during the Investor Day, our position right now is, yes, all right. But that implies really no degradation of the macro in a meaningful way from here kind of like a slow let the air out of a balloon as opposed to a shock. So, we're going to have a management meeting here as soon as this Q&A is done, and part of what we're going to do is basically go business by business and say, all right, what's your plan to meet your numbers for the year and what's your plan, if we run into trouble, right. We've got we have no choice but to run the corporation that way.
Richard Tobin: Well, we're modeled in a reduction in CapEx in beverage can make, right after going we had a pretty good three-year run of a lot of build out there and if you go look at what the big can makers are saying they're kind of pausing and getting their footing together. But that was modeled into our forecasts. And heat pumps, I think, the issues is your, so we'll leave that alone for the time being. On the retail fuelling side, it's actually the amount of negativity around that I think is overcooked, because we do see a lot of CapEx still there. We still expect a lot of consolidation there, which drives CapEx when those retail operations are, you basically have taking smaller stations and building much more larger complex stations, which is good for us. But Mike at the end of the day, plastics in terms of raw production of capacity expansion, particularly in Asia and North America is quite good despite energy costs moving up a little bit. So, the watch points for us is more credit tightness and how that affects CapEx for kind of not for big OEMs but for kind of like the second layer, that's where we think there may be some tightness.
Richard Tobin: The margins should go up into Q4. So you're rightly, if you go back and look at Q4 margin, we would expect Q1 margin that come down solely on production performance. So, we would expect it to come down but from a comp point of view from here, we'd expect to have accretive margins up until Q4 and then we'll see how we end the year because I think our margins are quite robust. On the vehicle, calling that market flat, right, so it's not a negative in terms of consolidated margin from the segment instead that's more of a top line comment, as opposed to a margin comment.
Richard Tobin: I think it's more Julian of the performance in terms of revenue and margin looks, comp to comp looks similar. Now, having said that, we had an $0.08 of EPS headwind of kind of below the line segment headwinds, which we believe dissipates. So I don't want to get into EPS accretion guidance quarter to quarter, but we did it. So, it looks -- if you look at Q2, if you look at the performance, relative performance Q1 to Q1 comp and do the same for Q2 to Q2 comp, it should look similar probably without some of the headwind that we saw on the below the line items.
Richard Tobin: No, but the price that we have, the price that the accretion from price overall is just peanut buttered over what we see the sequential revenue growth is for the full year. And so, it's not as if we've put new pricing out there. And so that book-to-bill is kind of more accretive that what we have modeled, at the end of the day, I'd have to go back and take a look in terms of mix but as you can imagine around here, calculating mix effect on that many revenue streams is a bit difficult. But, overall, Scott, it was, we knew we were carrying big backlogs into '23 and we knew, and our customers knew that our lead times were coming down quite a bit. So we would expect it kind of to do more of a bleed off of not necessarily the backlog, but it would reflect it in the lower order rates. But you know, like I said, in March we had a pretty good inflection in terms of orders, which allowed us to get above one because as I mentioned with the back, what we've got modeled in for backlog depletion. We don't need to be above one this year and that's why we're trying to kind of coach everybody into, let's not panic if we don't do above one. We don't need to be above one to hit our numbers.
Richard Tobin: Both, right. So, you had positive inflection and biopharma that we talked about. I think, retail fueling inflected positively, which is a good sign. But on the longest cycle side, plastics and polymers, which is a long cycle business booked very well. And we expect it to book very well again in Q2. So, it's both I mean, at the end of the day. So -- but we haven't even had the time to dissect it order by order. But I can tell you just in terms of it's not overly short cycle and it's an -- exclusively short cycle, because there is an element of long cycle in there, which you're going to see probably in our backlogs by the time we close Q2.
Richard Tobin: I think everybody overestimates the margin in Belvac, which is accommodated into our forecast for the full year beginning because as we mentioned. We've been kind of transparent about what the cycle was there. We would expect to see some kind of fade there, but it's not something that we can't mop up because CO2 systems and heat exchanger margins are at minimum flat to what we get in beverage can making.
Richard Tobin: That's pretty aggressive. Look, at the end of the day, as I mentioned, we actually did not give up margin going down. We just gave up the mix effect of that reduced volume on the segment itself. All I can tell you is we would expect on the way back up that from a margin mix point of view, it's clearly positive. And that's why I think that we're sitting, as I mentioned in my opening comments, we're trying our best to get to 30 for the full year, which implies some amount of positive. We know we have the compound positivity, but it implies some amount of growth in the second half of the year at some healthy biopharma margin. But more importantly as we went through in the Investor Day, if we strip out the COVID, the core business is growing 20%. So, if we get some growth in the back end, it's margin accretive and as we roll into '24, if we can keep on that trajectory then it becomes meaningful in terms of absolute profits and margin. But what I don't want to do is to tuck down the growth rates of the rest of the segment from a mix point of view because if they grow significantly themselves and you're going to have a little bit of a margin mix drag, but in absolute profits will take it.
Richard Tobin: In fueling solutions, I think that we're probably 90% there. We've taken a bunch of cost out last year, and then we took some further actions this year. So, the management team is doing a real good job of kind of getting their arms around positioning the cost structure of that business based on what we believe that demand is and the business model is going to be going from here. Having said that, the balance of the portfolio as opportunity in it, and I think if you go back and read the comments, I think I wrote into the fact that we would expect some further footprint actions to go on. And I think you'll begin to see some of that this year.
